probenecid has been researched along with Chronic Disease in 44 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 8.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| " A new xanthine oxidase inhibitor called febuxostat has been approved in 2009 for treatment of hyperuricaemia in gout." | 7.78 | Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. ( Asmahan, MI; Hilmi, BA; Rosman, A, 2012) |
| "No significant increase was noted in acute gout flare severity or duration among GA patients treated with early aggressive control of hyperuricemia using probenecid plus colchicine." | 5.69 | Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial. ( Chen, HC; Wei, JC; Yang, DH, 2023) |
| "Our review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily)." | 4.90 | Allopurinol for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| "We considered all randomised controlled trials (RCTs) or quasi-randomised controlled trials (controlled clinical trials (CCTs)) that compared uricosuric medications (benzbromarone, probenecid or sulphinpyrazone) alone or in combination with another therapy (placebo or other active uric acid-lowering medication, or non-pharmacological treatment) in adults with chronic gout for inclusion." | 4.90 | Uricosuric medications for chronic gout. ( Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R, 2014) |
| " Chronic hyperuricemia (uric acid serum levels >6." | 4.86 | Crystal arthropathies: recognizing and treating "the gouch". ( Quillen, DM, 2010) |
| "Gout is a clinical syndrome encompassing a group of metabolic diseases that are all characterized by abnormal uric acid metabolism." | 4.77 | Hyperuricemia and gout. ( German, DC; Holmes, EW, 1986) |
| " A new xanthine oxidase inhibitor called febuxostat has been approved in 2009 for treatment of hyperuricaemia in gout." | 3.78 | Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. ( Asmahan, MI; Hilmi, BA; Rosman, A, 2012) |
| " The drug is particularly useful in patients with chronic gouty arthritis and tophi, either refractory or allergic to probenecid, sulfinpyrazone, or allopurinol." | 3.65 | Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. ( Yu, TF, 1976) |
| " The use of allopurinol has been researched extensively and newer strategies for safer effective dosing are now recommended." | 2.58 | Gout - An update of aetiology, genetics, co-morbidities and management. ( Robinson, PC, 2018) |
| "His uric acid was 11 mg/dL despite maximal dosing of febuxostat." | 1.48 | Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. ( Case, R; Jester, G; Wentworth, B, 2018) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (65.91) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (9.09) | 29.6817 |
| 2010's | 9 (20.45) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, DH | 1 |
| Chen, HC | 1 |
| Wei, JC | 1 |
| Cicero, AFG | 1 |
| Fogacci, F | 1 |
| Kuwabara, M | 1 |
| Borghi, C | 1 |
| Case, R | 1 |
| Wentworth, B | 1 |
| Jester, G | 1 |
| Robinson, PC | 1 |
| Seth, R | 2 |
| Kydd, AS | 2 |
| Buchbinder, R | 2 |
| Bombardier, C | 2 |
| Edwards, CJ | 2 |
| Barber-Singh, J | 1 |
| Seo, BB | 1 |
| Nakamaru-Ogiso, E | 1 |
| Lau, YS | 3 |
| Matsuno-Yagi, A | 1 |
| Yagi, T | 1 |
| Xu, G | 1 |
| Xiong, Z | 1 |
| Yong, Y | 1 |
| Wang, Z | 1 |
| Ke, Z | 1 |
| Xia, Z | 1 |
| Hu, Y | 1 |
| Quillen, DM | 1 |
| Patki, G | 1 |
| Lipworth, W | 1 |
| Kerridge, I | 1 |
| Brett, J | 1 |
| Day, R | 1 |
| Hilmi, BA | 1 |
| Asmahan, MI | 1 |
| Rosman, A | 1 |
| HUEBER, EF | 1 |
| LUCKERBAUER, H | 1 |
| MORAWETZ, F | 1 |
| MARSON, FG | 1 |
| GAMP, A | 1 |
| TALBOTT, JH | 1 |
| FRITZE, E | 1 |
| MUELLER, HO | 1 |
| HOLLANDER, E | 1 |
| GUTMAN, AB | 1 |
| YU, TF | 3 |
| Dervan, AG | 1 |
| Meshul, CK | 1 |
| Beales, M | 1 |
| McBean, GJ | 1 |
| Moore, C | 1 |
| Totterdell, S | 2 |
| Snyder, AK | 1 |
| Meredith, GE | 2 |
| van Vliet, EA | 1 |
| Redeker, S | 1 |
| Aronica, E | 1 |
| Edelbroek, PM | 1 |
| Gorter, JA | 1 |
| Chen, YF | 1 |
| Carlile, JR | 1 |
| Beckman, EN | 1 |
| Arensman, RM | 1 |
| Fujiwara, Y | 1 |
| Takamitsu, Y | 1 |
| Ueda, N | 1 |
| Orita, Y | 1 |
| Abe, H | 1 |
| Eilon, A | 1 |
| Deutsch, E | 1 |
| Zelig, S | 1 |
| Baiatova, KV | 1 |
| Petroske, E | 1 |
| Callen, S | 1 |
| Emmerson, BT | 1 |
| Bowers, MB | 1 |
| Fiedelman, WM | 1 |
| Grajwer, LA | 1 |
| Mukhopadhyay, D | 1 |
| Grossman, BJ | 1 |
| Bazurov, GI | 1 |
| German, DC | 1 |
| Holmes, EW | 1 |
| Ball, GV | 1 |
| Freeman, D | 1 |
| Bergan, T | 1 |
| Brodwall, EK | 1 |
| Westlie, L | 1 |
| Oyri, A | 1 |
| Otto, W | 2 |
| Häntzschel, H | 1 |
| Sonninen, V | 1 |
| Riekkinen, P | 1 |
| Rinne, UK | 1 |
| Gottesbüren, H | 1 |
| Strohmeyer, G | 1 |
| Hedström, SA | 1 |
| Münnich, D | 1 |
| Straus, B | 1 |
| Binder, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for probenecid and Chronic Disease
| Article | Year |
|---|---|
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout S | 2021 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperu | 2018 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans | 2014 |
Uricosuric medications for chronic gout.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Chronic Disease; Controlled Clinical Trials as Topic; Femal | 2014 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Huma | 2010 |
Drug control of gout and hyperuricaemia.
Topics: Allopurinol; Arthritis; Chronic Disease; Colchicine; Gout; Humans; Indomethacin; Naproxen; Phenylbut | 1978 |
Hyperuricemia and gout.
Topics: Acute Disease; Adult; Allopurinol; Anti-Inflammatory Agents; Arthritis; Arthrography; Calcinosis; Ch | 1986 |
[What is certain in gout therapy?].
Topics: Acute Disease; Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Hydrogen-Ion Concentration; K | 1971 |
1 trial available for probenecid and Chronic Disease
| Article | Year |
|---|---|
Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial.
Topics: Arthritis, Gouty; Chronic Disease; Colchicine; Gout; Gout Suppressants; Humans; Probenecid; Symptom | 2023 |
35 other studies available for probenecid and Chronic Disease
| Article | Year |
|---|---|
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gou | 2018 |
Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chronic Disease; Disease Mo | 2009 |
Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cells, Cultured; Chronic Disease; Corp | 2010 |
Impact of exercise on mitochondrial transcription factor expression and damage in the striatum of a chronic mouse model of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Analysis of Variance; Animals; Chronic Disease; Corpus Striatum; Cytochrome | 2011 |
How clinical and research failures lead to suboptimal prescribing: the example of chronic gout.
Topics: Allopurinol; Chronic Disease; Drug Discovery; Drug Utilization; Gout; Gout Suppressants; Guideline A | 2011 |
Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Topics: Allopurinol; Chronic Disease; Contraindications; Febuxostat; Gout; Gout Suppressants; Humans; Male; | 2012 |
[Therapy of chronic gout with benemid and cortisone].
Topics: Arthritis, Gouty; Chronic Disease; Cortisone; Gout; Probenecid | 1954 |
Sodium salicylate and probenecid in the treatment of chronic gout; assessment of their relative effects in lowering serum uric acid levels.
Topics: Arthritis, Gouty; Blood; Chronic Disease; Gout; Humans; Probenecid; Salicylates; Sodium Salicylate; | 1954 |
[Medical treatment of chronic gout].
Topics: Arthritis, Gouty; Chronic Disease; Gout; Probenecid; Sulfanilamide; Sulfanilamides; Sulfonamides | 1957 |
Selected aspects of acute and chronic gouty arthritis; an internist's interpretation of an orthopaedist's experiences with gout and gouty arthritis.
Topics: Arthritis, Gouty; Chronic Disease; Colchicine; Gout; Humans; Orthopedics; Probenecid | 1958 |
[On probenecid treatment of chronic gout. Report of a severe complication of treatment].
Topics: Arthritis, Gouty; Chronic Disease; Gout; Humans; Probenecid; Uremia | 1962 |
[Uricosuria therapy of chronic gout].
Topics: Arthritis; Chronic Disease; Gout; Humans; Probenecid; Uric Acid; Urologic Diseases | 1963 |
Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis.
Topics: Arthritis, Gouty; Benzoic Acid; Body Fluids; Chronic Disease; Gout; Probenecid; Uric Acid; Uricosuri | 1951 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |
Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Casse | 2005 |
[Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication].
Topics: Adult; Antipsychotic Agents; Biogenic Amines; Chronic Disease; Female; Homovanillic Acid; Humans; Hy | 1984 |
Actinobacillus actinomycetemcomitans pneumonia.
Topics: Actinobacillus Infections; Adolescent; Ampicillin; Chronic Disease; Humans; Male; Pneumonia; Probene | 1984 |
Hypouricemia due to an isolated defect in renal tubular urate reabsorption.
Topics: Adult; beta 2-Microglobulin; Chronic Disease; Glomerulonephritis; Humans; Kidney; Male; Phosphates; | 1980 |
Hyperuricemia: a possible etiologic factor in chronic recurrent parotitis.
Topics: Adult; Chronic Disease; Humans; Male; Parotitis; Probenecid; Uric Acid | 1982 |
[Effect of long-term base therapy on the clinical picture of gout].
Topics: Adult; Allopurinol; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Gout; Human | 1981 |
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Axons; Brain; Cell Death; Chro | 2001 |
CSF acid monoamine metabolities as a possible reflection of central MAO activity in chronic schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chronic Disease; Female; Homovanillic Acid; Huma | 1976 |
Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.
Topics: Adult; Aged; Arthritis; Benzbromarone; Benzofurans; Chemical Phenomena; Chemistry; Chronic Disease; | 1976 |
Letter: Urinary tract infection.
Topics: Carbenicillin; Chronic Disease; Humans; Probenecid; Urinary Tract Infections | 1975 |
Chronic polymicrobial bacteremia.
Topics: Adolescent; Ampicillin; Blood Bactericidal Activity; Carbenicillin; Chronic Disease; Enterobacteriac | 1975 |
[A case of delayed diagnosis of leprosy].
Topics: Chronic Disease; Diagnostic Errors; Female; Humans; Leprosy; Middle Aged; Neurofibromatosis 1; Probe | 1986 |
Management of chronic and recurrent gout.
Topics: Adrenocorticotropic Hormone; Allopurinol; Chronic Disease; Colchicine; Dexamethasone; Diet Therapy; | 1971 |
Renal excretion of gentamicin and effect of probenecid.
Topics: Chronic Disease; Creatinine; Gentamicins; Half-Life; Humans; Kidney; Kidney Function Tests; Probenec | 1973 |
[Modern therapy of gout].
Topics: Acute Disease; Chronic Disease; Colchicine; Diet, Reducing; Female; Gout; Humans; Indomethacin; Kidn | 1972 |
Acid monoamine metabolites in cerebrospinal fluid in multiple sclerosis.
Topics: Acute Disease; Adult; Brain; Chronic Disease; Demyelinating Diseases; Female; Homovanillic Acid; Hum | 1973 |
General and local antibiotic treatment of chronic osteomyelitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Blood Sedimentation; C-Reactive Protein; Child; Chlor | 1969 |
Pathogenesis and medical management of chronic gouty arthritis.
Topics: Allopurinol; Chronic Disease; Colchicine; Gout; Humans; Joints; Kidney; Probenecid; Sulfinpyrazone; | 1970 |
[Treatment of typhus bacteria carriers].
Topics: Adult; Ampicillin; Bile; Carrier State; Cholecystectomy; Chronic Disease; Feces; Female; Humans; Mal | 1970 |
Problems and progress in geriatrics.
Topics: Acute Disease; Aged; Aging; Calcitonin; Cardiovascular Diseases; Chronic Disease; Diabetic Coma; Dia | 1968 |
[Clinical aspects of chronic gout].
Topics: Adult; Aged; Allopurinol; Anemia; Arthritis; Bicarbonates; Blood Sedimentation; Chronic Disease; Fem | 1966 |